Payment overview · 2025
General Payments
$251.87
15 reported records · 8 companies
Healthcare provider profile · identity verified
Todd E Bullock, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CANEYVILLE, KY · NPI 1104822360
Verified facts
What the public records show
CMS Open Payments records show Todd E Bullock, APRN received $251.87 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.31 | 30.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.25 | 19.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.69 | 12.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.23 | 12.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.40 | 7.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.37 | 6.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.49 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.13 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.87 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.31 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.31 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
232 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 635 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 530 | 128 |
| Omeprazole | Omeprazole | 437 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 90 |
| Lisinopril | Lisinopril | 431 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 97 |
| Metformin Hcl | Metformin Hcl | 364 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 57 |
| Potassium Chloride | Potassium Chloride | 281 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 56 |
| Furosemide | Furosemide | 233 | 56 |
| Gabapentin | Gabapentin | 232 | 31 |
| Jardiance | Empagliflozin | 232 | 36 |
| Losartan Potassium | Losartan Potassium | 229 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 65 |
| Buspirone Hcl | Buspirone Hcl | 206 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 49 |
| Trazodone Hcl | Trazodone Hcl | 168 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 46 |
| Warfarin Sodium | Warfarin Sodium | 159 | 16 |
| Famotidine | Famotidine | 151 | 36 |
| Sertraline Hcl | Sertraline Hcl | 147 | 38 |
| Simvastatin | Simvastatin | 145 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 31 |
| Carvedilol | Carvedilol | 137 | 34 |
| Eliquis | Apixaban | 134 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 131 | 24 |
| Meloxicam | Meloxicam | 126 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 25 |
| Montelukast Sodium | Montelukast Sodium | 123 | 25 |
| Allopurinol | Allopurinol | 122 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 118 | 28 |
| Atenolol | Atenolol | 116 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 31 |
| Celecoxib | Celecoxib | 108 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 21 |
| Tramadol Hcl | Tramadol Hcl | 101 | 18 |
| Ezetimibe | Ezetimibe | 94 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 23 |
| Glimepiride | Glimepiride | 86 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 18 |
| Benazepril Hcl | Benazepril Hcl | 76 | 18 |
| Lovastatin | Lovastatin | 74 | 13 |
| Meclizine Hcl | Meclizine Hcl | 73 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 12 |
| Baclofen | Baclofen | 59 | 12 |
| Finasteride | Finasteride | 57 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 40 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 16 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Ozempic | Semaglutide | 34 | 11 |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Nystatin | Nystatin | 31 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 26 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 13 |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 14 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Clonidine | Clonidine | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Veo Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.87 · 15 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error